The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | UK practice: pomalidomide in patients resistant to lenalidomide
Guy Pratt, MD, FRCP, FRCPath, of University of Birmingham, Birmingham, UK, reviews data coming from the OPTIMISMM study (NCT01734928). This sub-analysis looked at patients with multiple myeloma treated with pomalidomide, bortezomib and dexamethasone after one prior line of therapy in patients pre-treated with bortezomib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
